Compare SUUN & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUUN | TELA |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 51.2M |
| IPO Year | N/A | 2019 |
| Metric | SUUN | TELA |
|---|---|---|
| Price | $1.56 | $1.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $5.00 | $3.31 |
| AVG Volume (30 Days) | ★ 496.4K | 356.4K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $32,753,484.00 | ★ $77,055,000.00 |
| Revenue This Year | $127.67 | $18.39 |
| Revenue Next Year | $4.98 | $15.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $1.23 | $0.86 |
| 52 Week High | $6.43 | $3.10 |
| Indicator | SUUN | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 45.98 |
| Support Level | $1.56 | $1.10 |
| Resistance Level | $1.72 | $1.21 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 21.02 | 31.58 |
SolarBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.